Alan Burnett

2.7k total citations · 2 hit papers
14 papers, 1.4k citations indexed

About

Alan Burnett is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Alan Burnett has authored 14 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 7 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Alan Burnett's work include Acute Myeloid Leukemia Research (8 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Alan Burnett is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Alan Burnett collaborates with scholars based in United Kingdom, United States and Canada. Alan Burnett's co-authors include Meir Wetzler, Bob Löwenberg, Ken Mills, Mark D. Minden, Laurence J. Marton, Tino Schenk, Katja Hebestreit, Andreea C. Popescu, Weihsu Claire Chen and Carsten Müller‐Tidow and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Alan Burnett

14 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Therapeutic Advances in Acute Myeloid Leukemia

2011 588 citations Alan Burnett, Meir Wetzler et al. Journal of Clinical Oncology profile →
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

2012 502 citations Tino Schenk, Weihsu Claire Chen et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alan Burnett United Kingdom	8	977	856	192	182	165	14	1.4k
Carla Mazzone Italy	15	479 0.5×	576 0.7×	219 1.1×	191 1.0×	183 1.1×	47	951
Jesús Duque‐Afonso Germany	18	684 0.7×	468 0.5×	78 0.4×	148 0.8×	225 1.4×	46	1.1k
Justin M. Watts United States	17	560 0.6×	530 0.6×	169 0.9×	85 0.5×	193 1.2×	127	968
C. Vasselon France	11	625 0.6×	420 0.5×	139 0.7×	113 0.6×	273 1.7×	27	964
Paola Panetta Italy	14	440 0.5×	573 0.7×	162 0.8×	234 1.3×	145 0.9×	27	858
Victoria Grandage United Kingdom	9	492 0.5×	472 0.6×	147 0.8×	264 1.5×	177 1.1×	16	926
Sebastien A. Burel United States	15	972 1.0×	452 0.5×	119 0.6×	49 0.3×	109 0.7×	23	1.2k
Gianfranco Catalano Italy	13	380 0.4×	512 0.6×	105 0.5×	168 0.9×	93 0.6×	44	867
N. Roubi France	6	558 0.6×	377 0.4×	116 0.6×	83 0.5×	232 1.4×	8	809
Christian Wuchter Germany	18	1.0k 1.1×	1.1k 1.3×	372 1.9×	534 2.9×	490 3.0×	20	1.9k

Countries citing papers authored by Alan Burnett

Since Specialization

Citations

This map shows the geographic impact of Alan Burnett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Burnett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Burnett more than expected).

Fields of papers citing papers by Alan Burnett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Burnett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Burnett. The network helps show where Alan Burnett may publish in the future.

Co-authorship network of co-authors of Alan Burnett

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Burnett. A scholar is included among the top collaborators of Alan Burnett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Burnett. Alan Burnett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Schenk, Tino, Weihsu Claire Chen, Stefanie Göllner, et al.. (2012). Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nature Medicine. 18(4). 605–611. 502 indexed citations breakdown →

Burnett, Alan. (2011). ACUTE LEUKEMIAS XIII. Annals of Hematology. 90(S1). 25–76. 1 indexed citations

Burnett, Alan, Meir Wetzler, & Bob Löwenberg. (2011). Therapeutic Advances in Acute Myeloid Leukemia. Journal of Clinical Oncology. 29(5). 487–494. 588 indexed citations breakdown →

Knapper, Steven, P. Bruce White, Mark J. Levis, et al.. (2011). The Efficacy of the FLT3 Inhibitor Lestaurtinib in AML Depends on Adequate Plasma Inhibitory Activity (PIA), and Is Unaffected by Rising FLT Ligand Levels: An Update of the NCRI AML15 & 17 Trials. Blood. 118(21). 421–421. 6 indexed citations

Sato, Takashi, Xiaochuan Yang, Steven Knapper, et al.. (2011). FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 117(12). 3286–3293. 191 indexed citations

Jenkins, Christopher, Saman Hewamana, David Krige, Chris Pepper, & Alan Burnett. (2010). Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia. Leukemia Research. 35(5). 677–681. 16 indexed citations

Coles, Steven, Stephen Man, Robert K. Hills, et al.. (2010). Over-Expression of CD200 In Acute Myeloid Leukemia Mediates the Expansion of Regulatory T-Lymphocytes and Directly Inhibits Natural Killer Cell Tumor Immunity. Blood. 116(21). 491–491. 3 indexed citations

Jenkins, Christopher, Saman Hewamana, Amanda Gilkes, et al.. (2008). Nuclear factor‐κB as a potential therapeutic target for the novel cytotoxic agent LC‐1 in acute myeloid leukaemia. British Journal of Haematology. 143(5). 661–671. 20 indexed citations

Walsby, Elisabeth, Amanda Gilkes, Amanda J. Tonks, et al.. (2008). Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. British Journal of Haematology. 141(4). 483–493. 40 indexed citations

10.

Burnett, Alan. (2007). MRC trials in acute myeloblastic luekemia: Where have we got to?. Leukemia & lymphoma. 48(12). 2289–2290. 4 indexed citations

11.

Jenkins, Christopher, Ken Mills, Chris Pepper, & Alan Burnett. (2007). Cellular Aminopeptidase Inhibition as a Target for the Therapy of AML by the Novel Agent CHR 2797.. Blood. 110(11). 1608–1608. 5 indexed citations

12.

Mead, Adam J., David C. Linch, Robert K. Hills, et al.. (2005). Favourable Prognosis Associated with FLT3 Tyrosine Kinase Domain Mutations in AML in Contrast to the Adverse Outcome Associated with Internal Tandem Duplications.. Blood. 106(11). 334–334. 6 indexed citations

13.

Allford, Sarah, David Grimwade, Stephen E. Langabeer, et al.. (1999). Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML. British Journal of Haematology. 105(1). 198–207. 31 indexed citations

14.

Guinn, Barbara‐ann, M. T. Smith, Rose Ann Padua, Alan Burnett, & Ken Mills. (1995). Changing p53 mutations with the evolution of chronic myeloid leukaemia from the chronic phase to blast crisis. Leukemia Research. 19(8). 519–525. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact